Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL248 Target Snapshot

Neutrophil elastase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,265Compounds
794Assays
2Approved Drugs
5,764.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Neutrophil elastase shows approved-linked disease relevance led by genetic disorder. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P08246. Start with genetic disorder, then reuse UniProt P08246 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with genetic disorder, then reuse UniProt P08246 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
genetic disorder

Neutrophil elastase shows approved-linked disease relevance led by genetic disorder. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with genetic disorder because it currently carries approved-linked support. Linked drugs include .ALPHA.1-PROTEINASE INHIBITOR HUMAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neutrophil elastase as ChEMBL target CHEMBL248, mapped to UniProt P08246. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neutrophil elastase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL248
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08246
Neutrophil elastase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neutrophil elastase is the right protein anchor across sources, using UniProt P08246 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why genetic disorder is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNeutrophil elastase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP08246
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeutrophil elastase
UniProt AccessionP08246
Component TypeProtein
Sequence Length267 aa

Neutrophil elastase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Neutrophil elastase, mapped to UniProt P08246. Sequence length is 267 aa.

Mapped IDP08246
Review nameNeutrophil elastase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Neutrophil elastase shows approved-linked disease relevance led by genetic disorder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
genetic disorder
1 linked drug · 1 direct · 1 efficacy
Linked drug.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Approved-linked Approved
hemorrhage
1 linked drug · 1 direct · 1 efficacy
Linked drug.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Approved-linked Approved
lung disease
1 linked drug · 1 direct · 1 efficacy
Linked drug.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Late clinical Phase III
chronic obstructive pulmonary disease
2 linked drugs · 2 direct · 2 efficacy
Linked drug.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Linked drugALVELESTAT
Late clinical Phase III
Alpha-1-antitrypsin deficiency
1 linked drug · 1 direct · 1 efficacy
Linked drug.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Late clinical Phase III
heart disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSIVELESTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with genetic disorder because it currently carries approved-linked support. Linked drugs include .ALPHA.1-PROTEINASE INHIBITOR HUMAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasegenetic disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
6
Phase III
8
Phase II
Assay Mix

Activity Type Distribution

IC503,582.0
KI2,110.0
EC5063.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL538776 11.0 Ki 0.01 Preclinical
CHEMBL163414 10.96 Ki 0.011 Preclinical
CHEMBL348965 10.96 Ki 0.011 Preclinical
CHEMBL142100 10.89 Ki 0.013 Preclinical
CHEMBL114992 10.89 Ki 0.013 Preclinical
CHEMBL164352 10.89 Ki 0.013 Preclinical
CHEMBL543416 10.85 Ki 0.014 Preclinical
CHEMBL435666 10.85 Ki 0.014 Preclinical
CHEMBL140865 10.8 Ki 0.016 Preclinical
CHEMBL142526 10.68 Ki 0.021 Preclinical
Distribution

pChEMBL Value Distribution

198
5.0
194
5.5
223
6.0
262
6.5
388
7.0
431
7.5
440
8.0
440
8.5
158
9.0
39
9.5
pChEMBL
Approved Drugs

Approved Drugs

TELAPREVIR
CHEMBL231813
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

796
Total Assays
2,610
Tested Compounds
4
Assay Types
Binding — 753 assays, 2,610 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 679 2,441 7.3
cell-based format 27 10 7.3
tissue-based format 17 79 7.6
assay format 15 8 6.9
organism-based format 14 27 6.6
cell-free format 1 45 8.6
Functional — 35 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 14 2 7.6
tissue-based format 12 1 5.0
organism-based format 9 0 —
ADME — 6 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 6 11 5.1
Toxicity — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine